scholarly journals The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile

2020 ◽  
Vol Volume 14 ◽  
pp. 5515-5520
Author(s):  
Nicola Squillace ◽  
Elena Ricci ◽  
Barbara Menzaghi ◽  
Giuseppe Vittorio De Socio ◽  
Simone Passerini ◽  
...  
Keyword(s):  
Lipid Profile ◽  
Tenofovir Disoproxil Fumarate ◽  
Liver Enzymes ◽  
Tenofovir Alafenamide

scholarly journals Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV‐infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine

2018 ◽  
Vol 124 (4) ◽  
pp. 479-490 ◽  
Author(s):  
Purificación Cid‐Silva ◽  
Noelia Fernández‐Bargiela ◽  
Luis Margusino‐Framiñán ◽  
Vanesa Balboa‐Barreiro ◽  
Álvaro Mena‐De‐Cea ◽  
...  
Keyword(s):  
Lipid Profile ◽  
Tenofovir Disoproxil Fumarate ◽  
Tenofovir Alafenamide ◽  
Versus Treatment

Real-Life Impact on Lipid Profile of a Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected Patients

2020 ◽  
Vol 18 ◽  
Author(s):  
Jennifer Lagoutte-Renosi ◽  
Mylène Flammang ◽  
Catherine Chirouze ◽  
Geneviève BeckWirth ◽  
Fabienne Bozon ◽  
...  
Keyword(s):  
Renal Function ◽  
Lipid Profile ◽  
Tenofovir Disoproxil Fumarate ◽  
Real Life ◽  
Biological Data ◽  
Lipid Lowering ◽  
Lipid Lowering Therapy ◽  
Lowering Therapy ◽  
Significant Difference ◽  
Tenofovir Alafenamide

Background: Tenofovir disoproxil fumarate is a prodrug of tenofovir diphosphate that exposes patients to renal toxicity over the long term. Tenofovir alafenamide, a new prodrug, now makes it possible to reduce toxicity, but at the cost of an alteration in lipid profile. There is currently no recommendation for follow-up of lipid profile when switching from tenofovir disoproxil fumarate to tenofovir alafenamide. Objective: Our study aimed to evaluate the effects on renal function and lipid profile of a switch from tenofovir disoproxil fumarate to tenofovir alafenamide, and the consequences for patient management. Methods: Demographic, clinical and biological data was recorded from a retrospective clinical cohort study in real-life, including patients who switched from tenofovir disoproxil fumarate to tenofovir alafenamide. A descriptive analysis of the study population, with comparison of biological parameters using the paired Student t test for paired data was performed. Results: From January 2016 to January 2019, a total of 103 patients were included. There was no significant difference in renal function before vs after the switch in therapy (p=0.29 for creatinine, p=0.30 for phosphoremia). We observed a change in lipid profile, with a significant increase in total cholesterol (p=0.0006), HDL cholesterol (p=0.0055) and triglycerides (p=0.0242). Four patients received lipid-lowering therapy after switching. Conclusion: In patients who switch from tenofovir disoproxil fumarate to tenofovir alafenamide, lipid profile is altered, and may require initiation of lipid-lowering therapy. It seems necessary to monitor lipid parameters after this switch, despite the absence of an official recommendation.

scholarly journals Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Pierre-Emmanuel Plum ◽  
Nathalie Maes ◽  
Anne-Sophie Sauvage ◽  
Frédéric Frippiat ◽  
Christelle Meuris ◽  
...  
Keyword(s):  
Cardiovascular Risk ◽  
Viral Load ◽  
Weight Gain ◽  
Lipid Profile ◽  
Total Cholesterol ◽  
Tenofovir Disoproxil Fumarate ◽  
Negative Impact ◽  
People Living With Hiv ◽  
Tenofovir Alafenamide ◽  
Living With Hiv

Abstract Background As cardiovascular diseases represent the main cause of non-AIDS related death in people living with HIV (PLWH) with undetectable viral load, we evaluated lipid profile, weight gain and calculated cardiovascular risk change after switching from tenofovir disoproxil fumarate (TDF)-based regimens to tenofovir alafenamide (TAF)-based regimens. Methods For this retrospective study, we selected HIV-infected patients with suppressed viral load who fitted in one of the two groups below: First group (TDF/TDF): Patients treated continuously with TDF-based regimens. Second group (TDF/TAF): Patients treated with TDF-regimens during at least 6 months then switched to TAF-regimens while maintaining other drugs unchanged. Available data included date of birth, gender, ethnicity, lymphocyte T CD4+ count, weight, height, blood pressure, current/ex/non-smoker, diabetes mellitus, familial cardiovascular event, lipid profile, duration and nature of antiretroviral therapy. Lipid parameters, weight and calculated cardiovascular risk using 5-year reduced DAD score algorithm [Friis-Møller et al. in Eur J Cardiovasc Prev Rehabil 17:491–501, 2010] were analyzed in each groups. Results Switching from TDF to TAF resulted in a significant increase in triglycerides levels, total cholesterol and HDL cholesterol. LDL cholesterol and total cholesterol/HDL ratio did not show significant changes. Calculated cardiovascular risk increased after switch from TDF- to TAF-based therapy. Conclusions Together with favorable outcomes at the bone and kidney levels, potential negative impact of TAF on lipid profile should be included in the reflection to propose the most appropriate and tailored ARV treatment.

Comparative Pricing of Branded Tenofovir Alafenamide–Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate–Emtricitabine for HIV Preexposure Prophylaxis

2020 ◽  
Vol 173 (6) ◽  
pp. 507-508
Author(s):  
Rochelle P. Walensky ◽  
Tim Horn ◽  
Nicole C. McCann ◽  
Kenneth A. Freedberg ◽  
A. David Paltiel
Keyword(s):  
Tenofovir Disoproxil Fumarate ◽  
Preexposure Prophylaxis ◽  
Tenofovir Alafenamide
Sign in / Sign up

Export Citation Format

Share Document